Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Meth...Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Methods:Patients were treated with nab-paclitaxel at a dose of 125 mg/m2 on day 1 and 8,and S-1,80 to 120 mg/day on days 1-14 of a 21-day cycle.Treatments were repeated until disease progression or unacceptable toxicity occurred.The primary endpoint was objective response rate(ORR).The secondary endpoints were median progression-free survival(PFS),overall survival(OS),and adverse events(AEs).Results:The number of patients enrolled were 54,and 51 patients were evaluated for efficacy.A total of 14 patients achieved partial response(PR)with an ORR of 27.5%.The ORR varied by sites,with 53.8%(7/13)for gallbladder carcinoma,18.4%(7/38)for cholangiocarcinoma.The most common grade 3 or 4 toxicities were neutropenia and stomatitis.The median PFS and OS were 6.0 and 13.2 months,respectively.Conclusions:The combination of nab-paclitaxel with S-1 showed explicit antitumor activities and favorable safety profile in advanced BTC and could serve as a potential non-platinum and-gemcitabine-based regimen.展开更多
The purpose of this study was to investigate the efficacy and safety of oxaliplatin combined with tegafur,gimeracil and oteracil potassium(SOX regimen)and vinorelbine combined with Pt(NP regimen)in the treatment of ad...The purpose of this study was to investigate the efficacy and safety of oxaliplatin combined with tegafur,gimeracil and oteracil potassium(SOX regimen)and vinorelbine combined with Pt(NP regimen)in the treatment of advanced triple negative breast cancer(TNBC).First of all,88 patients with advanced breast cancer were selected and divided into observation group and control group with 44 cases each by random number method.Both groups received conventional supportive therapy.On this basis,SOX regimen was adopted in the observation group and NP regimen in the control group,and the efficacy,occurrence of toxic and side effects in the two groups were compared.The results showed that the objective effective rates and clinical benefit rates of the two groups were statistically significant(P<0.05).In addition,both groups had hand foot syndrome,diarrhea,liver function damage,decreased platelet(PLT)and other toxic side effects,but the incidence of rash,oral ulcer and pigmentation in the observation group was significantly lower than that in the control group(P<0.05).Therefore,both SOX regimen and NP regimen can effectively treat advanced TNBC adverse reactions,but SOX regimen was more effective.展开更多
目的探讨晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效。方法回顾性选取2019年1月—2023年1月歙县人民医院肿瘤内科收治的60例晚期恶性肿瘤患者,依据治疗方法分为替吉奥组和对照组,每组30例。替吉奥组患者接受替吉奥胶囊姑息治疗,对照组患者...目的探讨晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效。方法回顾性选取2019年1月—2023年1月歙县人民医院肿瘤内科收治的60例晚期恶性肿瘤患者,依据治疗方法分为替吉奥组和对照组,每组30例。替吉奥组患者接受替吉奥胶囊姑息治疗,对照组患者接受卡培他滨治疗。统计分析两组患者临床疗效、血清肿瘤标志物水平[血清癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha-fetal protein,AFP)、糖类抗原199(carbohydrate antigen 199,CA199)]、疼痛程度[视觉模拟评分法(Visual Analog Scoring,VAS)]、生存质量[卡式评分标准(Card Rating Scale,KPS)、日常生活能力(Daily Living Ability,ADL)、工具性日常活动能力量表(Instrumental Daily Activity Ability Scale,IADL)、生活质量量表(Quality Of Life Scale,QOL)]、不良反应发生情况、生存期。结果替吉奥组患者的总缓解率83.33%高于对照组,差异有统计学意义(χ^(2)=9.320,P<0.05)。替吉奥组患者的血清AFP、CEA、CA199水平、VAS评分均低于对照组,KPS评分、ADL评分、IADL评分、QOL评分均高于对照组,差异有统计学意义(P<0.05)。替吉奥组患者的不良反应发生率10.00%低于对照组,差异有统计学意义(χ^(2)=4.344,P<0.05)。替吉奥组患者的无进展生存期长于对照组,差异有统计学意义(P<0.05)。结论晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效显著。展开更多
文摘Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Methods:Patients were treated with nab-paclitaxel at a dose of 125 mg/m2 on day 1 and 8,and S-1,80 to 120 mg/day on days 1-14 of a 21-day cycle.Treatments were repeated until disease progression or unacceptable toxicity occurred.The primary endpoint was objective response rate(ORR).The secondary endpoints were median progression-free survival(PFS),overall survival(OS),and adverse events(AEs).Results:The number of patients enrolled were 54,and 51 patients were evaluated for efficacy.A total of 14 patients achieved partial response(PR)with an ORR of 27.5%.The ORR varied by sites,with 53.8%(7/13)for gallbladder carcinoma,18.4%(7/38)for cholangiocarcinoma.The most common grade 3 or 4 toxicities were neutropenia and stomatitis.The median PFS and OS were 6.0 and 13.2 months,respectively.Conclusions:The combination of nab-paclitaxel with S-1 showed explicit antitumor activities and favorable safety profile in advanced BTC and could serve as a potential non-platinum and-gemcitabine-based regimen.
文摘The purpose of this study was to investigate the efficacy and safety of oxaliplatin combined with tegafur,gimeracil and oteracil potassium(SOX regimen)and vinorelbine combined with Pt(NP regimen)in the treatment of advanced triple negative breast cancer(TNBC).First of all,88 patients with advanced breast cancer were selected and divided into observation group and control group with 44 cases each by random number method.Both groups received conventional supportive therapy.On this basis,SOX regimen was adopted in the observation group and NP regimen in the control group,and the efficacy,occurrence of toxic and side effects in the two groups were compared.The results showed that the objective effective rates and clinical benefit rates of the two groups were statistically significant(P<0.05).In addition,both groups had hand foot syndrome,diarrhea,liver function damage,decreased platelet(PLT)and other toxic side effects,but the incidence of rash,oral ulcer and pigmentation in the observation group was significantly lower than that in the control group(P<0.05).Therefore,both SOX regimen and NP regimen can effectively treat advanced TNBC adverse reactions,but SOX regimen was more effective.
文摘目的探讨晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效。方法回顾性选取2019年1月—2023年1月歙县人民医院肿瘤内科收治的60例晚期恶性肿瘤患者,依据治疗方法分为替吉奥组和对照组,每组30例。替吉奥组患者接受替吉奥胶囊姑息治疗,对照组患者接受卡培他滨治疗。统计分析两组患者临床疗效、血清肿瘤标志物水平[血清癌胚抗原(carcinoembryonic antigen,CEA)、甲胎蛋白(alpha-fetal protein,AFP)、糖类抗原199(carbohydrate antigen 199,CA199)]、疼痛程度[视觉模拟评分法(Visual Analog Scoring,VAS)]、生存质量[卡式评分标准(Card Rating Scale,KPS)、日常生活能力(Daily Living Ability,ADL)、工具性日常活动能力量表(Instrumental Daily Activity Ability Scale,IADL)、生活质量量表(Quality Of Life Scale,QOL)]、不良反应发生情况、生存期。结果替吉奥组患者的总缓解率83.33%高于对照组,差异有统计学意义(χ^(2)=9.320,P<0.05)。替吉奥组患者的血清AFP、CEA、CA199水平、VAS评分均低于对照组,KPS评分、ADL评分、IADL评分、QOL评分均高于对照组,差异有统计学意义(P<0.05)。替吉奥组患者的不良反应发生率10.00%低于对照组,差异有统计学意义(χ^(2)=4.344,P<0.05)。替吉奥组患者的无进展生存期长于对照组,差异有统计学意义(P<0.05)。结论晚期恶性肿瘤替吉奥胶囊姑息治疗的疗效显著。
